Hualan Biological (002007.SZ): The application for registration and clinical trials of the injectable drug Paboliuzhu Monoclonal Antibody by its subsidiary has been accepted.

Smart Finance News App, Huaren Biopharmaceuticals (002007.SZ) has announced that recently, its subsidiary Huaren Genetic Engineering Co., Ltd. (hereinafter referred to as "Genetic Company") has received the "Acceptance Notification" of the domestic production drug registration clinical trial application for Pembrolizumab Injection issued by the National Medical Products Administration.